stockrow
Friday 6 November 2026
Export CNSY’s income statement to Excel — free account
Cerenome, Inc.
CNSY Healthcare Biotechnology
Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024.
- Revenue
- −70.4%
- EPS
- −311.3%
- Free cash flow
- −31.5%
Quarter to June 2026, against a year earlier
0.64
0.03
−4.48%
Follow CNSY
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 3 | 3 |
| 40,893.33% | 1,063.84% | 272.11% | (614.05%) | ||
| (191.33%) | (229.51%) | (99.41%) | (214.01%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (532.77%) | |
Return on Tangible Assets |
(578.27%) | (846.32%) | (143.34%) | (565.53%) | |
Average Days of Receivables |
0.00 | 22.55 | 95.09 | 152.93 | |
Free Cash Flow per Share |
(3.79) | (6.69) | (3.27) | (3.41) | |
Free Cash Flow |
(16.30) | (20.81) | (21.72) | (23.55) | |
Capital Expenditures |
(0.57) | (0.04) | (0.88) | (1.37) | |
| Other line items | |||||
Cash ROIC |
(75.27%) | (154.12%) | (78.30%) | (300.79%) | |
Accounts Receivable Turnover |
0.00 | 10.03 | 7.19 | 3.60 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
— | 0.00 | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | 0.00 | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
145.00% | 160.73% | 183.10% | 297.57% | |
Selling, General and Administrative Expense of Revenue |
210.92% | 232.73% | 281.26% | 430.55% | |
Share Based Compensation of Revenue |
18.16% | 29.54% | 46.58% | 73.57% | |
Interest Coverage |
— | — | (27.64) | (42.11) | |
Operating CF/Net income |
0.64 | 0.79 | 1.31 | 0.85 | |
Depreciation/Fixed assets |
2.30 | 1.73 | 0.39 | 0.32 | |
Capex/Depreciation |
(0.91) | (0.08) | (2.23) | (3.02) | |
Revenue per Share |
1.22 | 1.68 | 0.78 | 0.61 | |
Operating CF per Share |
(3.66) | (6.68) | (3.14) | (3.21) | |
Capex per Share |
(0.13) | (0.01) | (0.13) | (0.20) | |
Capex to Sales |
0.11 | 0.01 | 0.17 | 0.33 |
Columns are period end dates · fundamentals updated 26 Oct 2026